Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7260054 | 0.94 | PAM (0.51) | CYP4F2CYP4A11CYP19A1PAMMMP1 | |
| SCHEMBL5049007 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11CYP19A1PAMAPP | |
| SCHEMBL11765846 | 0.83 | PAM (0.61) | CYP4F2CYP4A11PAMMMP1MMP2 | |
| SCHEMBL12672806 | 0.81 | CYP4F2 (0.65) | CYP4F2CYP4A11CYP19A1PAMAPP | |
| SCHEMBL5050338 | 0.80 | CYP19A1 (0.41) | CYP19A1APPMMP1MMP2MMP9 | |
| SCHEMBL15457003 | 0.79 | CYP19A1 (0.42) | CYP4F2CYP4A11CYP19A1APPMMP2 | |
| SCHEMBL28797524 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11CYP19A1PAMAPP | |
| SCHEMBL14472705 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11CYP19A1PAMAPP | |
| SCHEMBL19462887 | 0.78 | APP (0.44) | CYP19A1APPMMP1MMP2MMP9 | |
| SCHEMBL5050208 | 0.78 | APP (0.44) | CYP19A1APPMMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | CYP4F2 1623/4885CYP4A11 922/4885CYP19A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.